Skip to content

Direct and Indirect Impact of COVID-19 In Older Populations

COVID-19 Chez la Personne âgée de Plus de 70 Ans : Impact Direct et Indirect à 3 Mois.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04381312
Acronym
COVID-OLD
Enrollment
1000
Registered
2020-05-08
Start date
2020-04-09
Completion date
2021-10-09
Last updated
2020-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk Factors for COVID-19 Outcomes in Elderly Populations

Keywords

elderly, COVID 19, mortality, functional status

Brief summary

This study propose to describe risk factors for acute and long term mortality of COVID 19 in patients up to 70 years old.

Detailed description

In December 2019, Wuhan city in China, became the center of an outbreak of pneumonia due to a novel coronavirus SARS-CoV-2, which disease was named coronavirus disease 2019 (COVID19) in February, 2020, by WHO. The COVID19 is much more dangerous for people over 60 with a death rate of 3.6% after 60, 8.0% after 70 and 14.8% after 80 -and according to our Italian colleagues over 20% after 90- against 2.3% in the general population. The elderly patients exhibits more complications (ARDS, delirium, cardiac and renal insufficiency) needing intensive care, and often had multiple comorbidities and in particular: cardiovascular disease (10.5% mortality), diabetes (7.3%), chronic respiratory disease (6.3%) and hypertension (6%). Very few data are available the specific burden of Infectious diseases (ID) in older populations. The large majority of literature is often related to intrahospital or direct mortality and only recently arise the idea of indirect impact of ID particularly in that populations. In that meaning, ID may be considered as a trigger of other medical events such as myocardial infarction, stroke, or other specific outcomes such as functional decline; For the last 10 years, the Specific interest group GInGer ( Groupe Infectio-Geriatrique ) a network of infectiologist and geriatrician SPILF/SFGG) carried out several studies on different aspects of ID in theses populations and recently demonstrated the indirect and long term impact of influenza and Clostridioides difficile infections. As an example, In influenza study, death-rate increases from 12,2 % in hospital related death to 25% at 3 months with high rate of complications (57%), high rates of rehospitalisation (25%) and functional decline (35%) leading to high increase in nursing home admission. The cost of these indirect impact is high and underestimated. Because of incidence and comorbidities rates, severity of the actual French older COVID 19-infected older populations and because of the potential indirect and long term impact of COVID19 in these populations, it seems essential to know whether 3 month related death is largely higher as for influenza, to determine risk factors for intra hospital and long term death, measure acute and long term complications, and describe the impact of COVID 19 on specific ageing outcomes such as functional status at Month 3 (M3).

Interventions

None listed

Sponsors

University Hospital, Grenoble
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
70 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* \+ positive PCR confirmed COVID 19 (confirmed case) or positive Thoracic CT Scan - (probable case)

Exclusion criteria

* Direct admission in Intensive care.

Design outcomes

Primary

MeasureTime frameDescription
mortality3 months3-month survival curve
Risk factors for death3 monthsSpecific COVID 19 risk factors for death and geriatric risk factors for death

Secondary

MeasureTime frameDescription
describe all acute complicationsthrough study completion, an average of 1 yearprevalence of all medical usual complications and geriatric acquired complications, such as delirium, falls, complications, such as delirium, falls, malnutrition, pressure sore)
functional decline3 months post acute phaserates of Functional decline between basal status (before admission) and admission,and between basal and 3 months, and between Discharge and 3 month.
Rehospitalisation3 months post acute phasePrevalence of readmission to hospital
Describe clinical symptoms specific to old populationbefore and at admissionclinical symptoms (respiratory , non respiratory symptoms and Geriatric syndromes)
Admission in nursing home3 months post acute phasePrevalence of new nursing home admission
risk factors for 3-month functional decline, acute complication and admission to nursing home3 months post acute phaseDetermine risk factors for 3-month functional decline, acute complication and admission to nursing home
medical complications3 months post acute phasePrevalence of medical complication s ( new infectious disease, c cardiovascular, metabolic diseases and geriatric acquired complications, such as delirium, falls, complications, such as delirium, falls, malnutrition, pressure sore)
describe specific and non-specific treatments used for COVID 19through study completion, an average of 1 yearPrevalence and duration of specific treatments and non-specific treatments

Countries

France

Contacts

Primary ContactGaëtan Gavazzi, PhD Professor
ggavazzi@chu-grenoble.fr04 76 76 5421
Backup ContactSaber Touati, ARC
stouati1@chu-grenoble.fr047676

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026